Straits Times Index
3,260.03 -11.54 (-0.35%) S&P 500
4,326.51 -23.42 (-0.54%) Dow
34,160.78 -7.31 (-0.02%) Nasdaq
13,352.78 -189.34 (-1.40%) BTC-USD
35,690.12 -1,448.75 (-3.90%) CMC Crypto 200
810.05 -9.45 (-1.15%)
DiaMedica Therapeutics Inc. (DMAC)
| Previous close | 2.4100 |
| Open | 2.4400 |
| Bid | 2.3200 x 1400 |
| Ask | 2.3700 x 1200 |
| Day's range | 2.2550 - 2.5699 |
| 52-week range | 2.2000 - 10.8800 |
| Volume | |
| Avg. volume | 173,706 |
| Market cap | 60.546M |
| Beta (5Y monthly) | 2.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7720 |
| Earnings date | 08 Mar 2022 - 14 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.20 |
- Business Wire
DiaMedica Therapeutics to Present Research at International Stroke Conference
MINNEAPOLIS, January 25, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 – 11, 2022. For information about the event, visit: https://professional.heart.org/en/meetings/int
- Business Wire
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
MINNEAPOLIS, January 05, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine and drug development in large and small biopharmaceutical companies.
- Business Wire
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event
MINNEAPOLIS, December 13, 2021--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually from January 5-7, 2022.
